-
摘要: 钠-葡萄糖共转运蛋白2(sodium glucose cotransporter 2，SGLT2)抑制剂，最初是作为降糖药而开发的，是通过降低近段肾小管内葡萄糖的重吸收来降低血糖。在心脏保护方面，可通过降低心脏前后负荷、改善心脏能量代谢、改善心肌重构等机制，改善慢性心功能不全患者的预后。无论有无2型糖尿病，SGLT2抑制剂因其优异的心血管保护作用可预防射血分数降低的心力衰竭(heart failure with reduced ejection fraction，HFrEF)患者发生心力衰竭恶化，从而使HFrEF患者受益。但急性心力衰竭患者使用SGLT2抑制剂的有效性、安全性及合适的用药时机的相关研究仍较少，需进一步的探索。本文就急性心力衰竭患者应用SGLT2抑制剂的研究进行综述，以期为急性心力衰竭的诊治提供指导。
-
关键词:
- 钠-葡萄糖共转运蛋白2抑制剂 /
- 急性 /
- 心力衰竭
Abstract: Sodium-glucose-cotransporter-2 inhibitors were originally developed as hypoglycemic agents. It lowers blood glucose by reducing glucose reabsorption in the proximal renal tubules. Chronic cardiac insufficiency can be improved by reducing cardiac load, improving cardiac energy metabolism, improving cardiac remodeling, and other mechanisms. With or without T2DM, SGLT2 inhibitors can prevent HF deterioration in HFrHF patients due to their excellent cardiovascular protection and benefits for the patients. However, there are few studies on the efficacy, safety, and appropriate timing of SGLT2 inhibitors in patients with acute heart failure, and further exploration is needed. This paper reviews the application of SGLT2 inhibitors in the treatment of AHF patients to provide theoretical guidance for further study of AHF patients.-
Key words:
- SGLT2 inhibitors /
- acute /
- heart failure
-
-
[1] Strom JB, Sengupta PP. Predicting Preclinical Heart Failure Progression: The Rise of Machine-Learning for Population Health[J]. JACC Cardiovasc Imaging, 2022, 15(2): 209-211. doi: 10.1016/j.jcmg.2021.09.011
[2] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368
[3] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18): e895-e1032.
[4] Tsutsui H, Ide T, Ito H, et al. JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure[J]. J Card Fail, 2021, 27(12): 1404-1444. doi: 10.1016/j.cardfail.2021.04.023
[5] McDonald M, Virani S, Chan M, et al. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction[J]. Can J Cardiol, 2021, 37(4): 531-546. doi: 10.1016/j.cjca.2021.01.017
[6] Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data[J]. BMJ, 2015, 351: h4451.
[7] Ponikowski P, Voors AA, Anker SD, et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure][J]. Kardiol Pol, 2016, 74(10): 1037-1147. doi: 10.5603/KP.2016.0141
[8] Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2019, 74(15): 1966-2011. doi: 10.1016/j.jacc.2019.08.001
[9] Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion and perfusion status-impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry[J]. Eur J Heart Fail, 2019, 21(11): 1338-1352. doi: 10.1002/ejhf.1492
[10] Cleland JG, Chiswell K, Teerlink JR, et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function(PROTECT) Study[J]. Circ Heart Fail, 2014, 7(1): 76-87. doi: 10.1161/CIRCHEARTFAILURE.113.000284
[11] Kapoor JR, Kapoor R, Ju C, et al. Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction[J]. JACC Heart Fail, 2016, 4(6): 464-472. doi: 10.1016/j.jchf.2016.02.017
[12] Ambrosy AP, Pang PS, Khan S, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial[J]. Eur Heart J, 2013, 34(11): 835-843. doi: 10.1093/eurheartj/ehs444
[13] American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl. 1): S111-S134.
[14] Kaku K, Lee J, Mattheus M, et al. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease-Results From EMPA-REG OUTCOME®[J]. Circ J, 2017, 81(2): 227-234. doi: 10.1253/circj.CJ-16-1148
[15] Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial[J]. Circulation, 2021, 143(4): 326-36. doi: 10.1161/CIRCULATIONAHA.120.051783
[16] Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure[J]. N Engl J Med, 2021, 384(2): 117-128. doi: 10.1056/NEJMoa2030183
[17] Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial[J]. Eur Heart J, 2016, 37(19): 1526-1534. doi: 10.1093/eurheartj/ehv728
[18] Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study[J]. Eur J Heart Fail, 2019, 21(8): 998-1007. doi: 10.1002/ejhf.1498
[19] Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials[J]. Lancet, 2020, 396(10244): 121-128. doi: 10.1016/S0140-6736(20)30748-0
[20] Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial[J]. Nat Med, 2022, 28(3): 568-574. doi: 10.1038/s41591-021-01659-1
[21] Nakagaito M, Imamura T, Joho S, et al. Efficacy of Continuing SGLT2 Inhibitors on Outcomes in Patients with Acute Decompensated Heart Failure[J]. Int Heart J, 2021, 62(4): 885-890. doi: 10.1536/ihj.21-022
[22] Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure(EMPA-RESPONSE-AHF)[J]. Eur J Heart Fail, 2020, 22(4): 713-722. doi: 10.1002/ejhf.1713
[23] Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial[J]. Nat Med, 2022, 28(4): 809-813. doi: 10.1038/s41591-022-01703-8
[24] McMurray J, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. doi: 10.1056/NEJMoa1911303
[25] 廖梦阳, 廖玉华, 余淼, 等. SGLT2抑制剂治疗心力衰竭潜在机制的新认识[J]. 临床心血管病杂志, 2022, 38(1): 1-6. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202201001.htm
[26] 廖玉华, 余淼, 袁璟, 等. 心力衰竭SGLT2抑制剂临床应用的中国专家共识[J]. 临床心血管病杂志, 2022, 38(8): 599-605. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202208001.htm
-
计量
- 文章访问数: 1409
- PDF下载数: 210
- 施引文献: 0
下载: